Iron Deficiency Anemia Treatments
Recommendations for the management of iron deficiency anemia including oral and intravenous iron therapies.
Hematologic Disorders
FDA-Approved Biosimilars
A comparative list of biosimilars approved by the FDA including their reference products, dosage forms and indications.
Bleeding Disorder Treatments: von Willebrand Disease
Treatment options for von Willebrand Disease (VWD).
Thromboembolic Disorder Assessment: DVT/PE
Risk factors, prevention strategies, signs & symptoms, and general treatment options for deep vein thrombosis (DVT) and pulmonary embolism (PE).
Anticoagulant Dosing Conversions
Recommended dosing conversions for anticoagulants such as warfarin, heparin, and dabigatran.
Manufacturing Deficiencies Delay Decision on Eflapegrastim
Eflapegrastim is a novel, long-acting G-CSF comprised of 2 protein components, an analogue of G-CSF and an Fc antibody fragment.
Thromboembolic Disorders: Treatments
Anticoagulants, antiplatelets, and thrombolytics for the treatment and/or prophylaxis of venous and arterial thrombosis.
Bleeding Disorder Treatments: Hemophilia A
Treatment options for Hemophilia A including factors and other biologics.
Highlights of the 2021 Joint Guidelines for Managing von Willebrand Disease
These guidelines from ASH, ISTH, NHF, and WFH are intended to support patients, clinicians, and healthcare professionals in their decisions affecting the management of VWD.
- Loading...
Loading...
Next post in Bleeding Disorders
Loading... 
Loading...